Guardant Health, Inc.
NASDAQ:GHMedical - Diagnostics & Research
+$2.67 today
- Market cap
- $19.64B
- Beta
- 1.62
- P/E (TTM)
- -39.9
- EPS (TTM)
- -$3.30
Volume 1.50M
Average 2.21M
GH Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Guardant Health, Inc.NASDAQ: GH
Net Change in Cash · Q3 FY2026 · quarter ended Sep 2026
Net change in cash dips below year-ago levels
Q3 FY2026 net change in cash of $21.73M (cash outflow) fell 52.7% year over year, behind the +39698.6% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -26.3% a year.
Context
- Net change in cash amounted to 14.3% of revenue in FY2025, down 53.9 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -52.7% toward the trailing-twelve-month pace of +39698.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (140.34M) USD
- Year-over-year change
- +72.2%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (140.34M) | +72.2% |
| FY2024 | 2024-12-31 | (503.93M) | -150.8% |
| FY2023 | 2023-12-31 | 991.74M | +383.1% |
| FY2022 | 2022-12-31 | (350.34M) | -2.8% |
| FY2021 | 2021-12-31 | (340.69M) | — |
Net Change in Cash vs competitors
How GH compares with its peers on the latest reported figures
- GH's LTM Sep 2026 net change in cash of $456.49M is the largest of the 10 companies compared; the peer median is $2.59M.
- Its year-over-year change of +39698.6% is the highest of 9, against a peer median of -91.1%.
- Net change in cash amounts to 35.7% of revenue for GH, versus a peer median of 7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $456.49M | +39698.6% | -26.3% | 35.7% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $359.67M | — | — | 90.5% |
| LTM Jun 2026 | $91.48M | -55.0% | -30.1% | 3.4% | |
| LTM Jun 2026 | $68.16M | -91.8% | +24.8% | 41.2% | |
| LTM Mar 2026 | $43.88M | -444.5% | -61.3% | 13.7% | |
| LTM Mar 2026 | $25.93M | -484.6% | -75.7% | 7.6% | |
| LTM Mar 2026 | $25M | +643.5% | — | 3.0% | |
| LTM Jun 2026 | $9.18M | -95.4% | +56.9% | 1.2% | |
| LTM Mar 2026 | $7.97M | +30.4% | — | 8.3% | |
| LTM Mar 2026 | $2.59M | -90.4% | — | 4.0% | |
| Peer median (excluding GH) | $2.59M | -91.1% | -30.1% | 7.6% | |
Competitors are the stored peer set for GH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (384.77M) | (654.59M) | (479.45M) | (436.37M) | (416.28M) |
| Depreciation & Amortization | 22.27M | 35.96M | 42.88M | 42.39M | 39.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 151.45M | 94.69M | 90.76M | 140.41M | 166.22M |
| Change in Working Capital | (40.47M) | 61.56M | 53.84M | (60.86M) | (14.43M) |
| Accounts Receivables | (44.35M) | 375K | 8.38M | (21.39M) | (28.18M) |
| Inventory | (7.96M) | (20.93M) | (10.35M) | (9.14M) | (14.79M) |
| Accounts Payables | 8.64M | 60.33M | 0 | 0 | 0 |
| Other Working Capital | 3.2M | 21.79M | 55.81M | (30.34M) | 28.54M |
| Other Non-Cash Items | 42.5M | 152.91M | (33.01M) | 74.58M | 39.99M |
| Operating Cash Flow | (209.02M) | (309.46M) | (324.98M) | (239.86M) | (184.76M) |
| Capital Expenditures | (75.04M) | (77.46M) | (20.49M) | (35.09M) | (48.31M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (58.99M) |
| Purchases of Investments | (940.23M) | (327.72M) | (635.5M) | (314.82M) | (827.23M) |
| Sales of Investments | 952.11M | 555M | 1.5B | 88.6M | 307.32M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (63.16M) | 149.82M | 840.25M | (261.31M) | (627.2M) |
| Debt Repayment | (146K) | (71K) | 0 | 0 | 402.5M |
| Common Stock Issued | 0 | 0 | 493.12M | 14.84M | 377.81M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (45.01M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (66.68M) | (189.02M) | (15.74M) | (15.83M) | (64.17M) |
| Financing Cash Flow | (66.82M) | (189.09M) | 477.38M | (996K) | 671.13M |
| Effect of Forex Changes | (1.69M) | (1.6M) | (911K) | (1.77M) | 491K |
| Net Change in Cash | (340.69M) | (350.34M) | 991.74M | (503.93M) | (140.34M) |
| Free Cash Flow | (284.05M) | (386.92M) | (345.46M) | (274.94M) | (233.07M) |
Guardant Health, Inc.
NASDAQ:GH
Intrinsic Alpha fair value
Locked
Current Price
$145.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.